Megan Insco, MD, PhD

Dr. Insco studies advanced melanoma. Melanoma initiation and drug resistance rely heavily on factors that control gene expression. Proteins called Cyclin Dependent Kinases (CDKs) show promise as drug targets in multiple difficult-to-treat cancers and are enabling a method to “drug” the previously “undruggable” process of gene expression. She aims to determine whether any of the transcriptional CDKs could be an effective drug target in advanced melanoma. 

Shuibin Lin, PhD

Dr. Lin studies neuroblastoma cancers. Genetic amplification and aberrant expression of the oncogenes LIN28B and MYCN are associated with high-risk neuroblastoma and poor survival. Interestingly, these genes positively regulate each other and form a self-reinforcing feedback loop to drive neuroblastoma oncogenesis. His research aims to identify novel factors that interact with LIN28B/MYCN in tumor formation. He is characterizing a LIN28B-interacting long intergenic non-coding RNA (lincRNA) and will determine how the lincRNA functions to regulate neuroblastoma progression.

 

Alejandro Gutierrez, MD

It remains unclear why some patients' tumors can be cured with chemotherapy, whereas other tumors that appear to be nearly identical are completely chemoresistant. Dr. Gutierrez focuses on this issue in a particularly high-risk subset of T-cell acute lymphoblastic leukemia, a disease that most commonly affects older children and young adults. His goals are to define the molecular basis of resistance to conventional chemotherapy in patients with this disease, and to leverage this knowledge to develop a therapeutic strategy to restore chemosensitivity.